Search results
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Motley Fool via Yahoo Finance· 7 days agoFive years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoThe cancer vaccine reduced the likelihood cancer would return or patients would die by 49% after...
Moderna Announces Update on Investigational RSV Vaccine
Morningstar· 6 days agoThe FDA has informed Moderna that it is working to conclude...
US FDA pushes decision on Moderna's RSV vaccine to end of this month
Reuters via AOL· 6 days agoThe Food and Drug Administration's move prolongs the wait for Moderna's second approved product, but...
Will your last COVID vaccine work against new ‘FLiRT’ variants?
WJZY via Yahoo News· 4 days agoIn February, a federal immunization committee voted...the CDC says. Previously, health officials...
There might be stockpiles, but making an effective bird flu vaccine won’t be quick or easy
The Telegraph via Yahoo News· 2 days agoHealth officials have been steadfast in their assurances. The risk of H5N1 bird flu jumping into...
Genetics Played Role in Blood Clots Linked to COVID-19 Shots
Time Magazine· 5 hours agoAdenovirus-based vaccines, like the J&J and AstraZeneca shots that were later pulled from the...
The AstraZeneca vaccine – should you be worried?
The Telegraph via Yahoo News· 5 days agoEarlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between the British pharma company...
Moderna to Present at Upcoming Conferences in May/June 2024
The Sacramento Bee· 3 days agoModerna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Investor's Business Daily· 2 days agoThe deal is a negative for Covid vaccine rivals Pfizer and Moderna, Leerink Partners analyst David...